KORRO BIO INC

Insightful insider sale at KORRO BIO shows COO’s routine tax‑settlement, not a confidence drop; executives keep strong long‑term stakes amid rising stock, negative earnings‑price ratio.

CEO Aiyar Ram’s recent purchase of 50,000 Korro Bio shares boosts insider confidence in its RNA‑editing OPERA platform, signaling a bullish outlook for investors.

Investor alert: Lynx1 Capital’s recent buy‑in signals confidence in Korro Bio’s rare‑disease RNA‑therapy pipeline and a potential upside as the company edges toward phase‑II trials.

Insider buying surges at Korro Bio, signaling confidence in its RNA‑editing platform and a potential upside beyond the current $11.5 price.

Insider buying spurs optimism at Korro Bio: COO & execs lock in $1.2 M in zero‑cost options, signaling confidence in RNA‑therapy pipeline and upside potential.